Business
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.
Daiichi Sankyo announced on May 28 that it had entered an agreement with Syneos Health to form a coalition dedicated to bringing new cancer therapies to patients in a safe and effective manner.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
Accent Therapeutics and AstraZeneca forged a collaboration valued at about $1.1 billion to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer.
The company plans to use the money to advance its lead candidate, NDX-1017, into Phase II/III clinical trials.
The $7.4 billion raised would fund Gavi’s immunization programs between 2021 and 2025, which would help immunize 300 million children and potentially save 7 to 8 million lives.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 4, 2020.
Imago BioSciences will announce preliminary results from its Phase IIb clinical trial for myelofibrosis (MF) at the 25th European Hematology Association (EHA) Annual Congress that begins June 12, 2020.